Boehringer Ingelheim today announced that the indication for Spiriva (tiotropium) Respimat in asthma has been accepted by the regulatory authorities in the EU.  Spiriva Respimat is indicated as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800µg budesonide/day or equivalent) and long-acting beta2-agonists and who experienced one or more severe exacerbations in the previous year.

The new indication for Spiriva® Respimat® in asthma is based on the UniTinA-asthma large-scale, Phase III clinical trial programme which investigated adults with asthma who continued to have symptoms despite taking at least ICS or ICS/LABA therapy.

For more details, go to: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/08_september_2014_asthma.html